Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Nov 21, 2013; 19(43): 7500-7514
Published online Nov 21, 2013. doi: 10.3748/wjg.v19.i43.7500
Published online Nov 21, 2013. doi: 10.3748/wjg.v19.i43.7500
Role of innate immunity in the development of hepatocellular carcinoma
Rajagopal N Aravalli, Department of Radiology, University of Minnesota Medical School, Minneapolis, MN 55455, United States
Author contributions: Aravalli RN solely contributed to this paper.
Correspondence to: Rajagopal N Aravalli, PhD, Department of Radiology, University of Minnesota Medical School, MMC 292, Mayo Memorial Building, 420 Delaware Street S.E., Minneapolis, MN 55455, United States. arava001@umn.edu
Telephone: +1-612-6268174 Fax: +1-612-6265580
Received: August 27, 2013
Revised: September 29, 2013
Accepted: October 17, 2013
Published online: November 21, 2013
Processing time: 112 Days and 21 Hours
Revised: September 29, 2013
Accepted: October 17, 2013
Published online: November 21, 2013
Processing time: 112 Days and 21 Hours
Core Tip
Core tip: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. Growing incidence of HCC has generated immense interest to understand the mechanisms of disease at the physiological, cellular and molecular levels with the hope of developing novel therapeutics for the treatment of HCC. In the past few years, it has become clear that innate immunity plays a critical role in the development and progression of HCC. In this review, these new developments and possibilities of developing novel therapeutic options based on this newly gained knowledge are discussed.